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ABSTRACT
Predictive biomarkers are eagerly awaited in advanced colorectal cancer (aCRC). 
Targeted sequencing performed on tumor and baseline plasma samples in 20 patients 
with aCRC treated with regorafenib identified 89 tumor-specific mutations of which 
≥50% are also present in baseline plasma. Droplet digital PCR (ddPCR) assays were 
optimized to monitor circulating tumor DNA (ctDNA) levels in plasmatic samples collected 
throughout the treatment course and showed the importance of using the absolute value 
for ctDNA rather than the mutant/wild type ratio in monitoring the therapy outcome. 
High baseline cell free DNA (cfDNA) levels are associated with shorter overall survival 
(OS) (HR 7.38, P=0.001). An early increase (D14) in mutated copies/mL is associated 
with a significantly worse PFS (HR 6.12, P=0.008) and OS (HR 8.02, P=0.004). These 
data suggest a high prognostic value for early ctDNA level changes and support the use 
of blood-born genomic markers as a tool for treatment.
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INTRODUCTION
Regorafenib (Stivarga®, Bayer AG, Leverkusen, 
Germany) is one of the therapeutic options for patients 
with chemorefractory advanced colorectal cancer 
(aCRC). It is associated with a small overall survival (OS) 
improvement and significant toxicities including hand 
foot skin reactions, diarrhea, hypertension and fatigue [1]. 
Hence, there is a need to develop tools able to quickly 
identify patients unlikely to benefit from the treatment in 
order to spare them from unnecessary side effects.
Circulating cell-free DNA or cfDNA is currently 
under wide investigation as a potential biomarker for 
tumor response. Identification of cfDNA indicates the 
presence of extracellular nucleic acids in the circulation 
due to apoptosis or necrosis. Deriving from normal cell 
types and primary tumor cells, circulating and metastatic 
tumor cells, it is present in healthy individuals as well as 
in cancer patients, although usually in higher quantities in 
the latter [2]. The amount of cfDNA varies strongly and 
may overlap between healthy and cancer populations. In 
addition, metastatic cancer patients usually have higher 
cfDNA levels than the non-metastatic ones. Several 
studies have already described the inverse correlation 
between cfDNA levels and overall survival [3, 4]. In 
166 aCRC patients treated with regorafenib, Tabernero 
et al. showed that a high cfDNA baseline concentration 
was associated with shorter progression-free survival 
(PFS) and OS compared to patients with a lower cfDNA 
plasma concentration [5]. A fraction of the cfDNA in 
cancer patients is circulating tumor DNA (ctDNA), which 
represents the DNA liberated by the tumor cells after 
apoptosis or necrosis. Because ctDNA is released into 
the bloodstream, plasma samples can be used as “liquid 
biopsies”, allowing the detection and follow-up of tumor-
specific anomalies [2, 6, 7].
Recent developments in molecular technologies 
offer the possibility to screen the tumor molecular 
landscape in a relatively timely and cost effective manner 
[8]. The screening can be performed on tumor tissue 
collected during surgery, from a biopsy or on tumor 
DNA extracted from a patients’ plasma. Bettegowda 
and colleagues evaluated the effectiveness of ctDNA 
detection in a large cohort of 640 cancer patients by 
digital PCR technologies. Briefly, ctDNA was detected 
in more than 75% of patients with different solid tumor 
types including colorectal, ovarian, advanced pancreatic, 
gastroesophageal, bladder, breast, hepatocellular, 
melanoma, and head and neck [4], while more than half 
of patients with primary brain, prostate, renal or thyroid 
cancer do not exhibit detectable levels of ctDNA with 
current methods.
The assessment of ctDNA represents an emerging 
field of cancer research. Although ctDNA cannot be used 
to identify and locate the tumor origin, it might be an 
excellent technique to monitor events over time. Repeated 
measurements of ctDNA will be easily preferred over 
multiple tumor biopsies, which are invasive, expensive 
and often difficult to repeat. The proportion of ctDNA 
in cfDNA varies greatly, between 0.01% to more than 
90%, depending mainly but not only on disease staging, 
pushing the sensitivity boundaries of our current 
technologies [9, 10]. However, sensitivity of sequencing 
techniques is continuously improving and one assumes 
that these techniques will also be applied in situations 
with low levels of ctDNA (early-stage disease, minimal 
residual disease…) in the near future. Tie et al. recently 
published the first data on ctDNA fot the detection of 
residual disease in 230 patients with stage II colon cancer. 
They were able to show that ctDNA detection after colon 
resection identifies patients with high risk of disease 
recurrence [11].
With the exception of RAS mutations, up to now, 
knowledge on tumor genetics hardly influences the 
management of CRC and the understanding of the tumor 
history at a personalized level [12].
Taking into account the relatively narrow efficacy/
toxicity ratio for regorafenib in aCRC, and the lack of 
available biomarkers, the initial purpose of the clinical 
trial RegARd-C (NCT01929616) was to detect and 
analyze tumors unlikely to benefit from regorafenib using 
combined early metabolic assessment of response and 
modern biological armamentarium. The sample collection 
in RegARd-C is depicted in Figure 1.
We present hereunder the results of a small 
exploratory study on 20 patients included in the 
RegARd-C trial for which we had all necessary samples 
available at the time of analysis, aiming (i) to correlate 
Figure 1: Sample collection in the RegARd-C study.
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the findings of targeted gene sequencing for known 
oncogenes and tumor suppressor genes between tumor 
tissue and ctDNA in plasma, (ii) to cross-examine these 
findings in plasma samples with the use of the droplet 
digital PCR (ddPCR) technology and (iii) to assess the use 
of serial plasma samples to detect quantitative changes in 
those tumoral genomic biomarkers that would reflect on 
resistance to the drug [13].
The time-points selected for sample collection and 
the methods used for sample analysis open a window of 
opportunities in the search for successful biomarkers. 
More specifically, these biomarkers could define general 
therapeutic possibilities and early response assessment 
at the level of each individual patient, reflecting the very 
basic principles of personalized medicine. To the best of 
our knowledge, this study is the first to assess ctDNA as 
a potential early (after 14 days of treatment) biomarker 
for response assessment in aCRC with potential direct 
implications in clinical practice.
RESULTS
Targeted gene sequencing analysis
Mutations in 47 important target genes for CRC 
were identified in 100% of patients with an average of 5 
mutations per patient (range 1-10). A total of 89 mutations 
were identified in the tumor tissue, consisting of 81 
substitutions, 3 insertions and 5 deletions. Concordant 
with literature, the most common mutations were found 
in APC (70% of patients), TP53 (70%), KRAS (70%) and 
PIK3CA (40%) [8]. Patient characteristics and results are 
described in Supplementary Tables 1 and 2, respectively. 
Interestingly, in 1 patient we found both a variant in KRAS 
and in BRAF, although these variants have frequently 
been described as being mutually exclusive [14]. We also 
confirmed the presence of both mutations by conventional 
PCR. Discordance in KRAS status as assessed by targeted 
gene sequencing or conventional PCR at diagnosis was 
seen in 15% of the patients. More specifically, 1 patient 
was previously diagnosed with a KRAS mutation on 
codon 13 as part of the routine analysis, while this 
mutation was found neither by targeted gene sequencing 
nor by our in-house validated conventional PCR, which 
means that this patient would have had the opportunity 
to potentially benefit from anti-EGFR therapy after 
failure of the study medication. On the contrary, a KRAS 
mutation was detected by targeted gene sequencing (and 
confirmed with our in-house PCR) in two other patients 
previously diagnosed as being KRAS-wild-type. To 
reduce the variability in mutation detection due to tumor 
heterogeneity, analysis was always performed on the same 
FFPE tissue block (Supplementary Table 3).
Subsequently, via sequencing, we investigated 
whether these tumor-specific mutations were also 
detectable in plasma at baseline and at day 14, during the 
first regorafenib treatment cycle. Results for each patient 
are described in Supplementary Table 2. In summary, 
in 12 out of 20 patients (60%) all tumor tissue-specific 
mutations were also present (variant allele frequency, 
VAF>1%) in plasma at baseline. In 7 out of 20 patients 
(35%) tumor tissue-specific mutations were partially 
present in plasma at baseline. In 1 patient (RGR-54) none 
of the tumor tissue-specific mutations were found in any 
of the plasma samples (VAF>1%). In 4 out of 20 patients 
(20%) (RGR-2,28,35,43) tumor-specific mutations present 
in the baseline plasma sample could not be retrieved by 
sequencing in plasma after 2 weeks of regorafenib therapy 
(VAF>1%). 2 out of 20 patients (10%) (RGR-44, 58) had 
a mutation in plasma at baseline that was not detected in 
the tumor tissue.
Droplet digital PCR technology evaluation
The sequencing results were subsequently validated 
with the ddPCR technology. On average 3 mutations 
(range 1-4) were selected per patient based on the highest 
VAFs. All data are shown in Table 1, except for patient 
RGR-7 for which ddPCR raw data could not be interpreted 
due to a lack of generated droplets by ddPCR. A strong 
correlation between sequencing and ddPCR results in 
terms of fractional abundance (FA) was observed for 
tumor samples (R2=0.903, P=1.3 e-19), for plasma at 
baseline (R2=0.977, P=3.6 e-33) and for plasma at C1 (cycle 
1 of regorafenib treatment) (R2=0.961, P=6.2 e-28). The 
scatterplots are shown in Figure 2.
We then followed patients’ mutations throughout 
the course of their experimental treatment using ddPCR 
analysis of plasma samples. Importantly, the interpretation 
of the results based on ddPCR was heavily influenced by 
the way the data were represented. More specifically, 
ddPCR results can be expressed (i) as usually reported 
in the literature by FA, denoting the proportion of the 
mutant allele frequencies (mutated copies/wild-type 
copies + mutated copies while presuming that wild-type 
copies are constant over time) or (ii) by absolute value 
(mutated copies/ mL of plasma). In all patients, ddPCR 
detected a strong increase of the number of wild-type 
copies in plasma during the first cycle of regorafenib, 
thereby directly affecting the FA. To avoid the possible 
impact caused by changes in wild-type copy numbers, 
we conducted our experiments using the mutated copies/ 
mL of plasma variable over time. The impact of wild-type 
copy variations on FA and thus on the patient’s dynamic 
monitoring is illustrated in Figure 3.
ctDNA monitoring in patients treated with 
regorafenib therapy
Next, we analyzed whether plasma DNA could 
be used to detect patterns of resistance to treatment by 
monitoring the ctDNA of the 20 studied patients before 
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Table 1: Results of targeted gene sequencing analysis compared to ddPCR analysis on archived tumor samples 
and plasma samples at baseline (BL) and after 14 days (D14) of regorafenib therapy (cycle 1). Patient RGR-7 was 
excluded due to a poor quality blood sample at BL and D14. VAF, variant allele frequency
Patient Gene Mutation Variant
Targeted sequencing ddPCR
VAF (%) 
tumor
VAF (%) 
plasma baseline
VAF (%) plasma 
D14 (C1)
VAF (%) 
tumor
VAF (%) 
plasma baseline
VAF (%) 
plasma 
D14 (C1)
RGR-1 APC p.R213* c.637C>T2 16,83 26,13 16,55 11,4 26,2 11,84
KRAS p.A146V c.437C>T2 26,84 57,47 20,72 26 59,1 26,6
TP53 p.R175H c.524G>A2 34,94 67,46 28,94 33,2 71,8 33,4
RGR-2 APC p.Y1376* c.4128T>A2 35,55 2,05 <1 62,4 4 0
KRAS p.G12V c.35G>T2 18,97 WT WT 29,5 1,3 0,09
RGR-4 BRAF p.V600E c.1799T>A2 19,51 21,12 9,95 21,9 23,8 14,8
KRAS p.G12D c.35G>A2 7,14 WT WT 7,14 0,05 0,04
PIK3CA p.H1047R c.3140A>G2 36,24 36,18 23,55 31,1 41,1 24,4
RGR-7 PIK3R1 p.S102* c.305C>A2 19,08 44,53 49,27 20,6 44,8 -
TP53 p.H214R c.641A>G3 24,16 42,55 30,6 18,1 - -
RGR-14 KRAS p.G12D c.35G>A2 36,62 24,69 10,05 36,6 31,4 18,3
RGR-24 APC p.S1032* c.3095C>A2 18,73 54,17 12,58 27,6 41,7 19,1
RGR-26 KRAS p.G12S c.34G>A2 28,77 15,99 8,61 24,9 19,3 12,9
TP53 p.R196* c.586C>T2 37,5 20,32 12,35 28,1 23,3 13,2
RGR-28 SMAD3 p.F343L c.1029C>A 21,19 5,72 <1 17,7 7 0,98
TP53 p.R273H c.818G>A3 34,5 5,36 <1 47,5 11 1,7
RGR-30 NRAS p.G12V c.35G>T2 51,04 42,93 26 48,9 45,6 32,8
APC p.W685* c.2054G>A2 42,01 32,34 19,63 27 32 18,8
TP53 p.G245S c.733G>A 51,35 38,5 15,61 49,4 44 23,3
RGR-35 KRAS p.G12C c.34G>T2 13,21 7,9 <1 12,8 7,9 1,34
PIK3CA p.E545K c.1633G>A2 12,74 9,93 1,49 15,5 8,2 1,74
TP53 p.R248Q c.743G>A3 19,51 9,27 1,13 17 8,5 1,21
RGR-38 APC p.E941* c.2821G>T2 21,28 5,03 1,54 22,7 8,2 2,4
KRAS p.G12D c.35G>A2 19,94 2,78 1,64 23,1 8 1,9
RGR-43 NRAS p.G12D c.35G>A2 26,49 4,34 <1 26,8 7,1 0,27
APC p.R283* c.847C>T2 18,03 5,95 <1 31,6 7 0,15
TP53 p.R248Q c.743G>A3 37,72 7,11 <1 36,9 6,9 0,29
RGR-44 KRAS p.Q61H c.183A>C2 WT 12,54 10,4 WT 12,8 12
PIK3CA p.F83L c.247TTT>AAA 31,23 36,5 30,04 33,7 41,4 38
APC p.R232* c.694C>T2 12,57 1,5 1,46 14,87 1,3 1,19
RGR-46 KRAS p.G13R c.37G>C2 35,04 7,66 5 30,3 11,9 6,36
PIK3CA p.E545K c.1633G>A2 39,22 13,91 8,48 34,9 14 7,42
APC p.Q1429* c.4285C>T2 34,28 10,15 5,72 29,1 14,8 6,8
RGR-50 PIK3CA p.E542K c.1624G>A2 20,42 31,06 16,06 20,1 32 16,4
KRAS p.G12V c.35G>T2 22,79 54,82 29,03 22 60,8 39,1
TP53 p.R110P c.329G>C 24,14 39,57 19,4 28,4 43,6 19
(Continued )
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the start of regorafenib, during the first therapeutic cycle 
and then every 2 cycles until disease progression. Serial 
ctDNA concentrations of 5 randomly selected patients are 
represented in Figure 4. All other patient graphs are shown 
in Supplementary Figure 1. The time course of patient 
RGR-28 shows an immediate 4-fold drop in ctDNA levels 
at the beginning of treatment (Figure 4A). A 6-fold increase 
is detected just before clinical progression. An immediate 
decrease is also detected in patient RGR-2 at the beginning 
of treatment and a significant increase is seen in ctDNA at 
least 55 days before clinical disease progression (Figure 
4B). In this patient the kinetics of mutational levels 
observed between 2 mutations such as APC (Y1376*) and 
KRAS (G12V) were different upon disease progression, 
representing most probably that, although all clones have 
the APC mutation, KRAS-mutated and KRAS-wild-type 
subclones behave differently during treatment. Patient 
RGR-43 demonstrated an immediate drop in ctDNA 
during treatment, followed by an increase at least 57 days 
before clinical progression for all investigated mutations 
(Figure 4C). The important decline in ctDNA levels 
between the 2 ctDNA measurements surrounding the time-
point of progression can be explained, by the fact that this 
patient received combined cytotoxic chemotherapy with 
oxaliplatin, 5 Fluorouracil and folinic acid (FOLFOX) 
after disease progression but before plasma collection of 
circulating DNA. In contrast to the first three patients, 
patient RGR-46 showed a 4-fold increase in ctDNA for 
all mutations immediately after starting the regorafenib 
treatment. This patient progressed clinically 48 days 
after the start of the treatment (Figure 4D). Serial 
carcinoembryonic (CEA) levels were measured as part of 
standard clinical practice in half of the patients, but could 
not be correlated with the ctDNA evolution, as the time-
points of blood sample collection and analysis differed.
Circulating DNA dynamics and prognosis
Based on previous literature, we investigated 
whether baseline cfDNA levels were inversely correlated 
to PFS and OS. We measured the total amount of 
circulating free DNA, including the circulating non-
tumoral DNA as well as the circulating tumor DNA 
cfDNA levels. Although there was a trend, no significant 
difference was seen between high and low cfDNA 
concentration and PFS (HR 2.63, P=0.08, 95% CI 0.91-
7.64) (Figure 5A). However, our findings confirmed that 
a high baseline cfDNA concentration (higher than median) 
was associated with a significantly inferior OS compared 
to patients with a lower baseline cfDNA concentration 
(lower than median) (HR 5.20, P=0.003, 95% CI 1.78-
15.14) (Figure 5B). Also, the continuous univariate 
analysis per one-unit increase correlated significantly with 
OS (HR 1.66, P=0.001, 95% CI 1.22-2.24).
Furthermore, we examined if ctDNA dynamics 
during regorafenib therapy had a prognostic value. We 
therefore assessed increase (threshold of 0) or decrease 
in investigated mutated copies by measuring between 
baseline and day 14 of C1 of regorafenib therapy and 
correlated these results with PFS and OS. Our analysis 
showed that an increase of mutated copies per mL of 
plasma between baseline and day 14 is associated with a 
Patient Gene Mutation Variant
Targeted sequencing ddPCR
VAF (%) 
tumor
VAF (%) 
plasma baseline
VAF (%) plasma 
D14 (C1)
VAF (%) 
tumor
VAF (%) 
plasma baseline
VAF (%) 
plasma 
D14 (C1)
RGR-51 KRAS p.G12A c.35G>C2 35,34 25,84 16,99 32,2 29,1 19,6
APC p.Q1429* c.4285C>T2 35,43 24,32 15,41 30,7 29,8 18,87
TP53 p.G245S c.733G>A 47,14 36,86 21,07 49,8 43 25
RGR-54 KRAS p.G13D c.38G>A2 12,36 <1 <1 17,8 0,29 0,2
PIK3CA p.G1049R c.3145G>C 13,48 <1 <1 15,4 0 0,013
APC p.R232* c.694C>T2 20,13 <1 <1 19 0,06 0,1
RGR-56 TP53 p.R337C c.1009C>T 41,4 39,92 18,22 39,8 44,7 22,6
APC p.Q1367* c.4099C>T2 27,06 19,68 7,54 31 31,1 13,4
NOTCH1 p.A1104T c.3310G>A 31,09 16,87 7,9 27,9 17,8 8,4
RGR-58 KRAS p.G12C c.34G>T2 2,86 63,42 20,94 3,6 61,4 17,6
TP53 p.M237K c.710T>A2 1,47 64,11 19,59 1,16 63,4 24,9
RGR-61 APC p.A1492Cfs*1513 c.2510_2511insT2 30,85 19,9 20,3 35,6 24,5 22,5
KRAS p.Q61H c.183A>C2 33,36 23,27 32,9 36,3 31,8 38,4
TP53 p.R158H c.473G>A 63,7 27,62 29,85 67,6 35,3 38,9
FBXW7 p.A422Qfs*443 c.1262delC 61,42 46,72 31,5 60,9 34,3 38,5
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Figure 2: Correlation analyses of mutation frequency. Fractional abundance (FA%= mutated copies/ mutated copies + wild type 
copies) of all targeted mutations obtained by targeted sequencing and ddPCR in (A) FFPE tumor samples, (B) in plasma samples at baseline 
and (C) in plasma samples at 14 days after start of regorafenib treatment of 19 aCRC patients.
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Figure 3: ddPCR data analysis. The ddPCR results for one patient expressed as (A) mutated copies/ mL of plasma, (B) FA 
(mutated copies/wild-type copies + mutated copies) and as (C) Wild-type copies/ mL of plasma. In (A), an increase is seen in 
mutated copies/ mL between baseline (BL) and at day 14 of cycle 1 (C1). In contrast, a clear decrease is observed when using 
the FA. This difference can be explained by the 8-fold increase in WT copies between BL and C1.
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Figure 4: ctDNA and cfDNA status before and during regorafenib treatment. ctDNA concentrations and cfDNA for 5 
patients that received regorafenib therapy. Colored boxes below the graphs indicate the dose and the period during which treatment was 
administered. Grey vertical lines indicate the time-points of ctDNA analysis. Patient (A) shows an immediate drop (4-fold) in ctDNA 
levels at day 14. A 6-fold increase is detected at progression. The patient denoted in (B) also shows an immediate decrease in ctDNA at 
day 14 and a significant increase in ctDNA at least 48 days before clinical disease progression. Interestingly, both represented mutations 
behave differently upon disease progression. (C) After an immediate drop in ctDNA, an increase is detected at least 56 days before clinical 
progression. Interestingly, 6 days after progression this patient received FOLFOX therapy explaining the drop (dashed lines) in ctDNA 
levels between 2 ctDNA measurements surrounding the time-point of progression. In contrast, the patient in (D) showed a 4-fold increase 
in ctDNA for all clones immediately after starting the regorafenib treatment. The patient progressed clinically 48 days after the start of 
treatment. In parallel, a 12-fold increase is measured in total cfDNA between baseline and 14 days after the start of treatment. Patient RGR-
1 in (E) shows a high cfDNA level at baseline of 23.2μg/mL. In contrast, all measured mutations in ctDNA decrease between baseline and 
day 14 after start of regorafenib therapy. The colored boxes below the graphs indicate the dose and the period during which the treatment 
was administered.
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significantly worse clinical outcome with a median PFS 
of 1.6 months versus 5.3 months (HR 3.94, P=0.02, 95% 
CI 1.22-12.78) and a median OS of 4.5 months versus 10 
months (HR 5.37, P=0.01, 95% CI 1.42-20.30) (Figure 
5C, 5D). Moreover, we determined by multivariate 
analysis that a high cfDNA and an increase in ctDNA are 
independent factors both for PFS (high cfDNA HR 4.19, 
P=0.02, 95% CI 1.25-14.06, ctDNA increase HR 6.12, 
P=0.008, 95% CI 1.62-23.09) and OS (high cfDNA HR 
7.38, P=0.001, 95% CI 2.19-24.85, ctDNA increase HR 
8.02, P=0.004, 95% CI 1.93-33.36). There is no evidence 
for an association between cfDNA (high/low) and ctDNA 
(increase/decrease) with P-value=1 or between ctDNA and 
cfDNA as a continuous variable (P=0.81). An example 
of this independence of both markers is represented for 
patient RGR-1 in Figure 4E. This patient shows a high 
baseline cfDNA level which is in line with his short OS. 
However, all measured mutations in ctDNA decreased 
between baseline and 14 days after the start of treatment. 
Patient RGR-51 shows a high baseline cfDNA level. In 
contrast, all measured mutations in ctDNA increased 
between baseline and 14 days after the start of treatment 
(Supplementary Figure 1J). Since both patient RGR-
43 and patient RGR-61 received post-study treatment 
(respectively, FOLFOX and Panitumumab) which could 
affect the OS, both patients were removed in a second 
statistical analysis. Yet, the removal of these patients did 
not affect the prognostic value of ctDNA nor of cfDNA on 
OS both in the univariate and multivariate analysis.
DISCUSSION
Until recently, the measurement of tumoral 
molecular biomarkers in the context of clinical and 
therapeutic monitoring has been poorly investigated 
mainly due to the need of invasive biopsies to obtain serial 
tumor samples. Also, the detection of tumoral biomarkers 
was essentially done in the context of resistance to targeted 
Figure 5: Kaplan-Meier curves for OS and PFS in aCRC patients receiving regorafenib therapy. Survival curves are 
represented according to the level of (A, B) cfDNA in plasma at baseline for OS and PFS, respectively and according to (C, D) the increase 
or decrease of ctDNA levels between baseline (BL) and 14 days after the start of regorafenib therapy (D14). Two patients out of 20 were 
not included in the PFS analysis due to missing information on clinical progression. For ctDNA analysis, another patient was excluded due 
to a poor quality blood sample at C1.
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therapies. More importantly, tumor biopsies are prone to 
sampling error and may not represent the entire tumoral 
genetic landscape due to tumor genetic heterogeneity 
and clonal evolution [15]. Therefore, in the first part of 
the study, we tried to retrieve the mutations detected in 
the archived tumoral tissue by targeted sequencing in 
ctDNA plasma samples. If the same mutations were 
found, ctDNA in plasma samples can be judged as a fair 
representation of tumor characteristics. The frequency 
of detected mutations was similar to the one reported 
in the literature [8]. However, we found a worrisome 
discordance in 15% of our studied patients for the KRAS 
status between targeted sequencing and conventional 
PCR technologies. Those divergences could be linked to 
the tumoral genetic heterogeneity [16], although the same 
tissue blocks were used for both analyzes [15]. Also, since 
different methods with different limits of detection (LOD) 
were used in KRAS clinical routine mutational analyzes, 
we assume that lower tumor mutational frequencies than 
the LOD could have been not detected. Concerning RGR-
46, this patient appeared mutated at 35% in our targeted 
sequencing results while in the external center no KRAS 
mutation was detected. This discrepancy is presumably 
due to a non-detectable technical issue during analysis or 
to an historical patient identification error. KRAS mutation 
detection methods should be performed using the same 
standardized guidelines in order to obtain reproducible and 
reliable results.
Although, in our study the mutations detected in 
the tumor were fairly represented in the plasma, 5/20 
(25%) patients had at least one tumor-specific mutation 
totally absent in both plasma samples. Treatments given 
between the time of collection of the archived tumor and 
the plasma sample at the start of regorafenib may have 
had an effect on tumor clonal composition and evolution 
[17] or tumor clones may simply have been released at 
undetectable levels in the circulation [4]. Also, two new 
mutations in two patients were found in plasma samples 
that were not detectable in the archival tumor tissue. 
These findings as well could be explained by the fact 
that archived tumor tissue and baseline plasma samples 
were not collected simultaneously. This could also be 
linked to the spatial heterogeneity or clonal evolution. 
KRAS mutations could also have pre-existed in few 
tumor cells, and have expended due to KRAS-wild-type 
tumor resistance to cetuximab and panitumumab therapy. 
Data are still missing in literature regarding the clinical 
meaning of appearance/ disappearance of mutations after 
CRC treatment.
In addition, the sensitivity of the technology used 
might play a role as illustrated in patient RGR-4 i.e. 
where a KRAS (G12D) mutation was detected by ddPCR 
in the plasma but, at a very low level, probably below the 
sensitivity offered by the targeted sequencing technology. 
The LOD of the used targeted sequencing technology for a 
given mutant allele is about 1%, which is 10 times higher 
that the one offered by the ddPCR [18, 19]. In general, 
the FA measured by ddPCR strongly correlated with 
targeted sequencing data. The somewhat lower correlation 
(R2=0.90) observed for tumor samples compared to the 
plasma samples might be explained by the negative impact 
of fragmented FFPE DNA on ddPCR analysis.
Another important issue raised during our study 
was the choice of data representation for ddPCR. cfDNA 
includes both mutant and wild-type DNA derived from the 
tumor and from non-tumor tissue. Often, ddPCR data as 
well as targeted sequencing data are represented as FA or 
as the ratio of mutated alleles over wild-type alleles plus 
mutated alleles, using the wild-type copies as an intra-
patient control for exclusion of poor sample quality or 
poor sample handling during cfDNA extraction. This data 
representation would be correct and efficient as long as the 
wild-type copies are constant over time. Due to the choice 
of sample collection and cfDNA analysis at 14 days of 
treatment in our study, it became clear that the treatment 
may significantly affect the number of wild-type copies 
through toxicity on normal tissues, introducing a possible 
bias in the FA variable potentially affecting hugely the 
molecular monitoring of the patients disease. It is generally 
believed that cfDNA is released into the circulation by 
apoptosis and necrosis. Regorafenib is known to be toxic 
for various tissues including the gastrointestinal tract, skin, 
and liver. [20] It is reasonable to assume that damaged 
tissues could be the source of a massive release of wild-
type cfDNA in the blood circulation. This deserves further 
investigation. Since exercise, trauma, pregnancy etc. also 
affect the release of DNA in the bloodstream, caution 
should be taken when considering non-mutated cfDNA 
as a standard for data representation [21, 22]. Pallisgaard 
and colleagues recently suggested to use an external 
standardization method by spiking the plasma samples 
with quantifiable non-human DNA fragments to control 
for loss of DNA during sample preparation [23]. This 
proposal should be considered when measuring mutated 
copies over time.
Our results provide additional valuable information 
on tumor burden changes during treatment and allow us 
to correlate the molecular profile of patients with their 
clinical follow-up. The need to follow several mutant 
alleles in order to provide a reliable molecular monitoring 
for each individual patient makes such a strategy 
difficult to translate into clinical practice as the design 
and optimization of such personalized assays is time 
consuming and costly. Also, many but not all detected 
mutations were followed over time. The average time 
between an increase in ctDNA in at least one mutant clone 
and clinical progression should be calculated on a larger 
patient cohort. In future analyses, a targeted sequencing 
analysis will be performed at progression in order to try 
to explore the existence of potentially newly acquired 
tumoral clones under treatment, or the appearance of 
tumoral subclones present but not detectable at diagnosis.
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Interestingly, in a substantial proportion of patients, 
an increase in ctDNA burden preceded the clinical or 
radiological progression. We also confirmed the known 
inverse correlation between cfDNA at baseline and OS. In 
contrast to previous literature, the cfDNA measured (in μg/
mL) at baseline in this study contains the total amount of 
circulating free DNA, including the circulating non-tumoral 
DNA as well as the circulating tumor DNA. Although non-
tumor cfDNA can be influenced by variety of reasons [22], 
the efficacy and speed of our analysis technology should 
outweigh this limitation and could potentially be more 
easily translated to the clinical practice, as reinforced by 
the fact that our results are in line with current literature 
(measured as genome equivalents of DNA per mL [5]). If 
this correlation is confirmed in larger cohorts, it would allow 
for stratification of patients according to a strongly validated 
prognostic variable, easily accessible for clinicians. This 
may have a tremendous impact on treatment choices and 
stratification of patients in future clinical studies. Finally, 
our analysis showed that an increase of mutated copies per 
mL of plasma as early as 14 days after the start of treatment 
is associated with a significantly worse clinical outcome 
in aCRC patients treated with regorafenib independently 
from cfDNA levels. To the best of our knowledge, we 
are the first to demonstrate that the measurement of the 
mutant allele burden performed before treatment and at 14 
days in the context of regorafenib treatment may have a 
predictive/ prognostic value in aCRC patients paving the 
way towards an early treatment personalization. Although 
our preliminary data strongly suggest that the change in 
ctDNA mutation levels could be used as a tool to predict 
early-response, this should be confirmed in the whole 
patients’ population of the RegARd-C study and thereafter 
in a prospective randomized study. If confirmed, its clinical 
relevance could also be determined in aCRC patients 
receiving other treatments than regorafenib.
While our analysis included only 20 patients, they 
all received the same treatment and were followed in a 
standardized manner with regular sample collections. 
Moreover, this preliminary analysis provided highly 
significant results regardless of the sample size and 
remaining independent risk factors in multivariate 
analysis. We are currently validating these very promising 
data in whole population of patients included in the clinical 
trial RegARd-C. As serial PET scans were performed at 
baseline and 14 days after the start of regorafenib, future 
analyzes will also include the correlation of PET data and 
molecular analyzes in plasma.
MATERIALS AND METHODS
Study design and participants
RegARd-C was a prospective multicentric academic 
trial with a non-randomized design in patients with 
aCRC refractory to standard therapy. The study aimed 
at identifying those patients who draw no benefit from 
treatment with regorafenib using FDG-PET metabolic 
imaging. In total 141 patients were included in the study 
and patients received oral regorafenib once a day for the 
first 3 weeks of a 4-week cycle starting at a dose of 160 
mg/day. The starting dose could be reduced following 
intolerable side-effects. Patients were monitored until 
disease progression, unacceptable toxicities or any other 
reason (study withdrawal, loss for follow-up, death…). 
Genomic sample analysis was performed on a subgroup of 
20 patients (composition of RegARd-C patient subgroup, 
Supplementary Table 1), selected due to their sample 
availability. Only patients who signed the study informed 
consent were considered in this study. The baseline patient 
demographics and disease characteristics are described in 
Supplementary Table 1. PFS was calculated as the time 
till progression/death, whatever occurred first. For cfDNA 
PFS analysis, 2 patients (RGR-51, 56) were excluded due 
to missing information on clinical progression. Patient 
RGR-7 was excluded for ctDNA PFS and OS analysis due 
to poor quality of the blood samples.
Sample collection and preparation
Blood samples for plasma extraction samples were 
collected at baseline and after two weeks of treatment. 
After that they were obtained every two cycles until disease 
progression or up to 1 year after the start of therapy. Whole 
blood was also collected at baseline. Previously obtained 
formalin fixed paraffin embedded (FFPE) primary (18/20) 
or metastatic tumor tissue (2/20) was gathered at study entry. 
Prior to tumor DNA extraction, hematoxylin and eosin 
stained slides were created from (FFPE) tumoral tissue. 
These slides were assessed by a pathologist for locating 
the regions where tumor cellularity was maximal (>50%). 
These regions were then used for DNA extraction using the 
QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany). 
Blood samples, collected in EDTA tubes were centrifuged 
at 2000xg for 15 minutes at 4°C within 1h of sample 
collection to separate the plasma from the peripheral blood 
cells. Next, plasma samples were stored at -80°C until cell-
free circulating DNA (cfDNA) extraction was performed of 
3mL of plasma using the QIAmp circulating nucleic acid kit 
(Qiagen). DNA from whole blood was extracted with the 
QIAamp DNA blood Maxi kit (Qiagen). DNA was quantified 
using the Qubit® 2.0 fluorometer and the Qubit® dsDNA 
HS assay kit (Life-Technologies, Gent-Brussels, Belgium). 
Multiple (3-6) cfDNA extractions and quantifications of 
plasma were performed for 4 patients to measure the intra-
patient extraction variability. No significant differences in 
cfDNA quantification were seen for either patient.
Targeted gene sequencing
Mutation analysis of tumor DNA was performed 
with the Ion Torrent technology (Life Technologies, 
Oncotarget17767www.oncotarget.com
Carlsbad, CA) available at OncoDNA, Gosselies, 
Belgium. The tumor DNA and cfDNA from whole blood 
samples were sequenced with the Onco-CRC panel 
including a screening of 47 genes classically mutated in 
CRC (Supplementary Table 4, panel A) with a sequencing 
coverage of 500x–1000x (Supplementary Table 2). Tumor-
specific mutations were defined by comparing mutations 
founded in tumor and matched whole blood samples, and 
subsequently tracked in 10 ng of plasma DNA samples 
(sequencing coverage of 25.000x). Additionally, about 
2800 other variants from the 50 most commonly reported 
oncogenes and tumor suppressor genes were tracked in the 
plasma (OncoDNA, Gosselies, Belgium) (Supplementary 
Table 4, panel B). Targeted sequencing detected KRAS and 
BRAF mutations were also analyzed with the COBAS® 
KRAS and COBAS® BRAF mutation tests (Roche 
Diagnostics Limited, Rotkreuz, Switzerland).
Droplet digital PCR and data analysis
ddPCR materials and methods as well as the 
supplementary data were written following the digital 
MIQE guidelines [24]. DdPCR experiments were 
performed on the Bio-Rad QX200 ddPCR system (Bio-
Rad, Hercules, USA). Briefly, a combination of ddPCR 
Supermix (no UTP) for probes and specific paired 
PrimePCR™ ddPCR™ Mutation Detection Assays 
(Bio-Rad, Hercules, USA) were used to detect and 
quantify the variants (Supplementary Table 5). Some 
PrimePCR™ ddPCR™ Mutation Detection Assays were 
custom designed by Bio-Rad (sequences proprietary to 
the Bio-Rad company). Prior to the mutation analysis, an 
optimization process of ddPCR Mutation Detection Assays 
was done including several steps in order to use the assays 
with a maximum of reliability and reproducibility between 
each experiment (Supplementary Materials).
For each assay reaction we maximized the 
amount of unamplified DNA by using 7.6-223.5 ng/
reaction for cfDNA samples and 77.4-454 ng/reaction 
for tumoral DNA. In each reaction we added 12 μL of 
ddPCR™ Supermix for probes (no dUTP) (Bio-Rad # 
186-3024USA), 1.2 μL of mutation and reference assays 
and water to reach a final volume of 24 μL. For droplet 
generation, 20 μL of this ddPCR mixture volume was 
loaded into each DG8 cartridge well (Bio-Rad #186-
4008, USA) along with 70μL of droplet generation oil for 
probes (Bio-Rad # 186-3030, USA). Next, the cartridge 
was placed in the QX200™ Droplet generator™ (Bio-
Rad) in order to generate approximately 20,000 water-
oil emulsion droplets. 40 μL of the emulsion was 
then carefully pipetted into a 96-well plate, sealed 
with a PX1™ PCR plate sealer (Bio-Rad) and finally 
placed in a T100™ thermal cycler (Bio-Rad) using the 
recommended thermal cycling protocol (Supplementary 
Table 6). DdPCR data was processed using QuantaSoft 
V1.7.4 software (Bio-Rad) to obtain the concentration, 
reported in copies of target/μl of reaction, and fractional 
abundance (FA) of the mutated alleles in the wild-type 
background. The resulting copies per μL of reaction 
were adjusted depending on the volume of ctDNA used 
(raw data are shown in Supplementary Tables 7 and 8). 
The threshold that determines if droplets are considered 
as positive is manually adjusted based on experimental 
setups wherein the false-positive rate (FPR) was 
estimated for each PrimePCR™ ddPCR™ Mutation 
Detection Assay. The FA per reaction is calculated as a 
percentage (%) of the (number of total mutated copies)/ 
(number of total mutated copies + number of total wild-
type copies). If a sample had too low positive events 
or a total amount of droplets lower than 10,000, the 
reaction was repeated at least twice in independent runs 
to validate the results. For FFPE samples we accepted 
an amount of droplets starting from 9000. Primary 
tumor DNA was used as positive control and DNA from 
whole blood as negative control for each assay reaction 
in every ddPCR run. Also, a no-template control (NTC) 
was always included as a negative control for the control 
assay.
Statistical analysis
Statistical analyses were performed by using 
Graphpad Prism 6 and SAS 9.4. Gaussian distributions 
were determined via the D’Agostino & Pearson omnibus 
normality test. Depending on the normal distributions, the 
correlation of targeted gene sequencing data and ddPCR 
was analyzed using the Pearson correlation coefficient 
or nonparametric Spearman correlation test. Also the 
cfDNA was correlated to OS and PFS using the same 
statistical tests. The univariate and multivariate analysis 
tests for OS and PFS were performed with the Cox’s 
proportional hazards model. Kaplan-Meier survival 
estimates were calculated for each group (decrease or 
increase in mutational burden between baseline and 
day 14 of cycle 1 and high or low cfDNA levels). The 
association between cfDNA (higher/lower than median) 
and ctDNA (increase/decrease) was measured with the 
Fisher Exact test and with the Mann-Whitney test for the 
continuous analysis.
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